Mitochondria transplantation alleviates cardiomyocytes apoptosis through inhibiting AMPKα‐mTOR mediated excessive autophagy

Abstract The disruption of mitochondria homeostasis can impair the contractile function of cardiomyocytes, leading to cardiac dysfunction and an increased risk of heart failure. This study introduces a pioneering therapeutic strategy employing mitochondria derived from human umbilical cord mesenchymal stem cells (hu‐MSC) (MSC‐Mito) for heart failure treatment. Initially, we isolated MSC‐Mito, confirming their functionality. Subsequently, we monitored the process of single mitochondria transplantation into recipient cells and observed a time‐dependent uptake of mitochondria in vivo. Evidence of human‐specific mitochondrial DNA (mtDNA) in murine cardiomyocytes was observed after MSC‐Mito transplantation. Employing a doxorubicin (DOX)‐induced heart failure model, we demonstrated that MSC‐Mito transplantation could safeguard cardiac function and avert cardiomyocyte apoptosis, indicating metabolic compatibility between hu‐MSC‐derived mitochondria and recipient mitochondria. Finally, through RNA sequencing and validation experiments, we discovered that MSC‐Mito transplantation potentially exerted cardioprotection by reinstating ATP production and curtailing AMPKα‐mTOR‐mediated excessive autophagy.